{"id":1073,"date":"2018-12-04T15:55:08","date_gmt":"2018-12-04T15:55:08","guid":{"rendered":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/"},"modified":"2018-12-04T15:55:08","modified_gmt":"2018-12-04T15:55:08","slug":"ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia","status":"publish","type":"post","link":"https:\/\/kuwaitallergyclinic.com\/en\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/","title":{"rendered":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia"},"content":{"rendered":"

Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. <\/p>\n

Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. Read More<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1073","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"\nIbrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic\" \/>\n<meta property=\"og:description\" content=\"Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Kuwait Allergy Clinic\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-04T15:55:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kuwaitallergyclinic.com\/wp-content\/uploads\/2026\/08\/logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"425\" \/>\n\t<meta property=\"og:image:height\" content=\"141\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/#\\\/schema\\\/person\\\/c158c5c6b9e118a532f4a3c59fdcba8d\"},\"headline\":\"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia\",\"datePublished\":\"2018-12-04T15:55:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/\"},\"wordCount\":45,\"articleSection\":[\"News & Articles\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/\",\"url\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/\",\"name\":\"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/#website\"},\"datePublished\":\"2018-12-04T15:55:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/#\\\/schema\\\/person\\\/c158c5c6b9e118a532f4a3c59fdcba8d\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/news\\\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/#website\",\"url\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/\",\"name\":\"Kuwait Allergy Clinic\",\"description\":\"Kuwait Allergy Clinic\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/#\\\/schema\\\/person\\\/c158c5c6b9e118a532f4a3c59fdcba8d\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/kuwaitallergyclinic.com\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic","og_description":"Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. Read More","og_url":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/","og_site_name":"Kuwait Allergy Clinic","article_published_time":"2018-12-04T15:55:08+00:00","og_image":[{"width":425,"height":141,"url":"https:\/\/kuwaitallergyclinic.com\/wp-content\/uploads\/2026\/08\/logo.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/#article","isPartOf":{"@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/"},"author":{"name":"admin","@id":"https:\/\/kuwaitallergyclinic.com\/#\/schema\/person\/c158c5c6b9e118a532f4a3c59fdcba8d"},"headline":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia","datePublished":"2018-12-04T15:55:08+00:00","mainEntityOfPage":{"@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/"},"wordCount":45,"articleSection":["News & Articles"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/","url":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/","name":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia - Kuwait Allergy Clinic","isPartOf":{"@id":"https:\/\/kuwaitallergyclinic.com\/#website"},"datePublished":"2018-12-04T15:55:08+00:00","author":{"@id":"https:\/\/kuwaitallergyclinic.com\/#\/schema\/person\/c158c5c6b9e118a532f4a3c59fdcba8d"},"breadcrumb":{"@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/kuwaitallergyclinic.com\/news\/ibrutinib-plus-rituximab-superior-to-standard-treatment-for-some-patients-with-chronic-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kuwaitallergyclinic.com\/"},{"@type":"ListItem","position":2,"name":"Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia"}]},{"@type":"WebSite","@id":"https:\/\/kuwaitallergyclinic.com\/#website","url":"https:\/\/kuwaitallergyclinic.com\/","name":"Kuwait Allergy Clinic","description":"Kuwait Allergy Clinic","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kuwaitallergyclinic.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/kuwaitallergyclinic.com\/#\/schema\/person\/c158c5c6b9e118a532f4a3c59fdcba8d","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ff3a8bec02cb1df85e4bcb3ab0c97545ed9f33b9a554ed3b04b822998408e81?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/kuwaitallergyclinic.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/posts\/1073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/comments?post=1073"}],"version-history":[{"count":0,"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/posts\/1073\/revisions"}],"wp:attachment":[{"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/media?parent=1073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/categories?post=1073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kuwaitallergyclinic.com\/en\/wp-json\/wp\/v2\/tags?post=1073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}